AC Immune, Lilly Begin Dosing Subject with Tau Morphomer Inhibitor

By Chris Wack

AC Immune SA (ACIU) said Wednesday it has begun dosing the first subject in a Phase 1 study of its ACI-3024, an investigational oral small molecule Tau Morphomer inhibitor that will be studied in neurodegenerative diseases that are characterized by the presence of pathological Tau aggregates.

The clinical-stage biopharmaceutical company said in a release that this is the first significant advancement in its collaboration with Eli Lilly & Co. (LLY).

AC Immune said ACI-3024 is the primary focus of a license and collaboration agreement between it and Lilly to research and develop small molecule Tau aggregation inhibitors for the treatment of Alzheimer's disease and other neurodegenerative diseases. The collaboration combines AC Immune's proprietary Morphomer discovery platform and early development experience with Lilly's clinical development expertise and commercial capabilities in central nervous system disorders.

AC Immune said it will conduct the initial Phase 1 development of the Morphomer Tau aggregation inhibitors while Lilly will fund and conduct further clinical development.

AC Immune said the Phase 1 trial is a randomized dose study with open label food effect and pharmacodynamics assessment arms to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of ACI-3024 in healthy volunteers.

Write to Chris Wack at [e-mail]

(END) Dow Jones Newswires

July 17, 2019 07:35 ET (11:35 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.